UTICA, N.Y. — ConMed Corporation (NASDAQ: CNMD) on Wednesday announced that it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from the NASDAQ Global Market.
The Utica–based surgical-device manufacturer expects to begin trading on the NYSE effective at the open of markets on Feb. 10, the firm announced.
“We are excited to be joining the NYSE on the actual day of ConMed’s 50th anniversary. With this move, we join the group of high-performing medical-device companies traded on the NYSE. We are grateful for the long and valued partnership with NASDAQ and look forward to a productive relationship with the NYSE,” Curt Hartman, CEO of ConMed, said in a statement.
(Sponsored)
Criminal Liability for Employment Law Violations?
New York employers are often surprised to learn that wage law violations can lead to criminal penalties in addition to financial penalties. Whether payroll is outsourced, or a staffing agency
You Filed Your 2022 Tax Returns, Now Let’s Look Ahead
Another busy tax filing season is behind us and with a return to normalcy this year, without significant processing delays at the Internal Revenue Service (IRS), we can look forward.
The company’s shares will continue to trade on the NASDAQ until the transfer is completed and will continue to trade under the ticker “CNMD” after the move to the NYSE.
“We are delighted to welcome ConMed, an innovator in the medical device industry, as it transfers its listing to the NYSE,” John Tuttle, vice chairman and chief commercial officer of NYSE Group. “We look forward to collaborating with the company and continuously delivering the benefits of our unique market model and world-class services.”
ConMed is a medical technology company that produces surgical devices and equipment for minimally invasive procedures. The firm’s products are used by surgeons and physicians in specialties that include orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology.
For the full year of 2019, ConMed posted net income of $28.6 million, or 97 cents a share, down 31 percent from $40.8 million, or $1.41 a share, during 2018.
Contact Reinhardt at ereinhardt@cnybj.com
